Wall Street brokerages expect that Xeris Pharmaceuticals Inc (NASDAQ:XERS) will report earnings of ($1.21) per share for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for Xeris Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($1.17) and the lowest estimate coming in at ($1.24). Xeris Pharmaceuticals reported earnings of ($0.98) per share during the same quarter last year, which would suggest a negative year-over-year growth rate of 23.5%. The company is expected to report its next quarterly earnings results on Wednesday, March 4th.
According to Zacks, analysts expect that Xeris Pharmaceuticals will report full-year earnings of ($4.79) per share for the current year, with EPS estimates ranging from ($4.84) to ($4.73). For the next financial year, analysts anticipate that the company will post earnings of ($3.37) per share, with EPS estimates ranging from ($3.68) to ($3.06). Zacks Investment Research’s earnings per share averages are an average based on a survey of analysts that that provide coverage for Xeris Pharmaceuticals.
Xeris Pharmaceuticals (NASDAQ:XERS) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($1.22) EPS for the quarter, topping analysts’ consensus estimates of ($1.23) by $0.01. The firm had revenue of $0.32 million during the quarter, compared to analysts’ expectations of $0.20 million. Xeris Pharmaceuticals had a negative return on equity of 150.08% and a negative net margin of 6,697.33%.
A number of analysts recently commented on the company. Mizuho reiterated a “buy” rating and set a $22.00 price objective on shares of Xeris Pharmaceuticals in a research report on Thursday, November 21st. Royal Bank of Canada set a $18.00 price objective on Xeris Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, August 7th. ValuEngine cut Xeris Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Monday, September 30th. Finally, Zacks Investment Research upgraded Xeris Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, November 16th.
In other Xeris Pharmaceuticals news, insider Paul R. Edick purchased 17,935 shares of the firm’s stock in a transaction on Monday, November 25th. The shares were purchased at an average cost of $8.55 per share, with a total value of $153,344.25. Following the purchase, the insider now owns 172,935 shares in the company, valued at $1,478,594.25. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Steven Prestrelski sold 27,700 shares of the firm’s stock in a transaction dated Friday, October 11th. The stock was sold at an average price of $9.00, for a total value of $249,300.00. Company insiders own 7.43% of the company’s stock.
A number of large investors have recently modified their holdings of XERS. Bank of Montreal Can acquired a new stake in Xeris Pharmaceuticals in the 2nd quarter worth about $26,000. Tower Research Capital LLC TRC acquired a new stake in Xeris Pharmaceuticals in the 2nd quarter worth about $42,000. Marshall Wace North America L.P. acquired a new stake in Xeris Pharmaceuticals in the 1st quarter worth about $71,000. Metropolitan Life Insurance Co NY acquired a new stake in Xeris Pharmaceuticals in the 3rd quarter worth about $100,000. Finally, Susquehanna International Group LLP acquired a new stake in Xeris Pharmaceuticals in the 2nd quarter worth about $118,000. 66.37% of the stock is currently owned by hedge funds and other institutional investors.
Xeris Pharmaceuticals stock traded up $0.14 during midday trading on Wednesday, reaching $8.94. 125,806 shares of the company were exchanged, compared to its average volume of 196,196. The company has a market capitalization of $241.07 million, a price-to-earnings ratio of -1.79 and a beta of -0.39. The firm’s 50-day simple moving average is $8.34 and its 200-day simple moving average is $10.21. Xeris Pharmaceuticals has a 1 year low of $6.85 and a 1 year high of $20.90. The company has a debt-to-equity ratio of 1.33, a quick ratio of 5.96 and a current ratio of 5.96.
Xeris Pharmaceuticals Company Profile
Xeris Pharmaceuticals, Inc, a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations. Its proprietary XeriSol and XeriJect formulation technologies allow for the subcutaneous and intramuscular delivery of highly-concentrated, ready-to-use formulations of peptides, proteins, antibodies, and small molecules using commercially available syringes, auto-injectors, multi-dose pens, and infusion pumps.
Read More: Profit margin is different from the revenue
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Xeris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xeris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.